The Lp(a) Global Summit 2025 was an exclusive, high-level event dedicated to shaping the future of cardiovascular health by focusing on Lipoprotein(a) [Lp(a)]. Hosted in Brussels on the occasion of Lp(a) Awareness Day, this summit brought together the world's leading experts, policymakers, and patient advocates to advance global policy discussions, scientific breakthroughs, and healthcare strategies.
The event culminated in the release of the Brussels International Declaration on Lp(a), a policy-driving document that will influence cardiovascular health initiatives at the European and international levels.
This first-ever global summit was a milestone initiative of the Lp(a) International Taskforce, convened by FH Europe Foundation and chaired by Prof. Florian Kronenberg.
We are honoured to announce that the First Global Lp(a) Summit was held under the patronage of the Polish Presidency of the Council of the European Union. This esteemed endorsement underscores the significance of addressing elevated Lipoprotein(a) [Lp(a)] in global cardiovascular health initiatives.
Read the post-event press release
The Declaration is currently in the process of publication. Once officially published, it will be available online and open for public endorsement here.
If you would you like to endorse the Brussels International Declaration once it is publicly available, please fill out the information below:
Bringing together world-renowned researchers, forward-thinking policymakers, dedicated advocates, and individuals with lived experience of elevated Lp(a), the event created a powerful space for knowledge exchange and collective action. Voices from across disciplines and backgrounds came together with a shared purpose: to shine a light on Lp(a) and accelerate progress toward meaningful change.
Each speaker played a vital role in challenging the status quo and inspiring meaningful dialogue. More than just experts, they brought courage, determination, and a personal commitment to change. Their stories and contributions left a lasting impact, reminding us that every voice matters—and matters deeply.
Zanfina Ademi is a Professor of Health Economics and leads the Health Economics and Policy Evaluation Research group at the Faculty of Pharmacy and Pharmaceutical Sciences, Monash University. Their research vision is to improve health and welfare and reduce inequities in society by using high-quality health economic evidence for decision-making. Prof. Ademi is currently a member of the Economics Sub Committee of the Pharmaceutical Benefits Advisory Committee which assesses clinical and economic evaluations of medicines submitted for listing on the Pharmaceutical Benefits Scheme (PBS). Their research has impacted policy decision-making processes and attracted $44.6M in funding. Prof. Ademi has published >170 original publications, including >33,000 citations (FWCI of 26.66); 50% published in the top 1% most viewed worldwide, 1/2 as first, co-first, and senior author. Prof Ademi’s work is published in top-tier journals, BMJ, NEJM, Lancet, JAMA Cardiology, JAMA Paediatrics, European Heart Journal, Neurology, Diabetes Care, PharmacoEconomics and Value in Health. Their research has led to changes in many clinical guidelines and policies: lipid management; listing of services on the Medical Benefits Scheme [MBS]); heart failure therapies (listing by PBS and Federal Office of Public Health [FOPH], Switzerland); cardiovascular disease PBS listing; kidney disease [KDIGO] guidelines; listing of new hyperkalaemia drug to FOPH, Sweden, Switzerland, Scotland and UK; Lifestyle interventions; listing of herpes zoster vaccine [FOPH] and; evidence of low-value care to disinvest combination therapy for Alzheimer’s disease.
Her work in familial hypercholesterolaemia provided evidence of the cost-effectiveness of family genetic testing followed by treatment for familial hypercholesterolaemia in Australia. This model supported a successful Medical Services Advisory Committee application recommending genetic screening as a reimbursed item. Moreover, their work on genetic testing in children provided evidence for the first time that testing children and treating them early in life was a cost-saving over their lifetime.
Nicola Bedlington was the first Executive Director and Secretary General of the European Patients Forum from 2006 to 2019. Nicola was also the founding Director of the European Disability Forum, (1996 to 1999). Prior to this, she headed the NGO unit within HELIOS, a European Commission Action Programme promoting equal opportunities for disabled people (1991-1996). From 2004 to 2006, she led the Environment and Schools Initiatives Secretariat (ENSI), an international government-based network set up by OECD focussing on Education for Sustainable Development.
Nicola is based in Vienna, and has recently set up Millwater Partners, a consultancy company focused on health, engagement and sustainability. In this role, she has undertaken several projects in the field of cardiovascular health, including authoring the European Action Plan on Cardiovascular Health. She is also advising a number of global initiatives focused on meaningful patient engagement (Patient Focused Medicines Development (PFMD), From Testing to Targeted Treatment (FT3) and the Global Centre for Person -Centred Value Based Healthcare.
Nicola is the Senior Policy Advisor to the FH Europe Foundation, and supported the recent Campaign on FH Paediatric Screening, authoring the Prague Declaration on FH Paediatric Screening. She is the project lead for the Lp(a) preparatory phase.
Marius Geantă is President and Co-Founder of the Center for Innovation in Medicine, a research, innovation and health policy oriented civil society organisation.
Dr. Marius Geantӑ is also:
Marius is a pioneer in the field of personalised medicine in Europe and is involved in some pan-European innovative healthcare projects, such as Information Technology: The Future of Cancer Treatment, DigiTwins Consortium, Public Health Genomics Network, PECAN, Building Blocks for Personalised Medicine, ReThinkHPVaccination, National Cancer Competency Center, Uncan EU initiative and others.
As President of the Centre for Innovation in Medicine, Marius is the coordinator of “State of Innovation in Medicine” Annual Report and the organiser of the high-level events - Science meets Politicians (in partnership with Romanian Parliament), and Personalised Medicine Conference (two editions in partnership with Romanian Presidential Administration).
He has more than 15 years of experience and expertise in the field of health and science communication as editor in chief and publisher of many medical journals and health communication platforms. As expert in the field of health innovation, Dr. Marius Geantă is usually invited by the mainstream media (TV, radio, websites) to discuss topics of interest - he has more than 1000 interviews in the context of Covid-19 pandemic.
Marc Rijken is from The Netherlands, is 50 years old, happily married to his wife Manon and
together they have three daughters (age 21, 19 and 16). Marc works for the Royal Dutch
Airline as a Learning & Talent manager in the centre of expertise for L&D.
Marc is also a person living with elevated Lp(a) and has suffered from several incidents since 2014 (2 heart attacks, 1 open heart surgery, 7 bypasses, 1 stent). He was diagnosed with elevated Lp(a) at the age of 46, over 4 years after his second heart attack (in 2017).
In 2022 Marc became a patient ambassador, actively working to raise awareness about elevated Lp(a) including advocacy work at the European Parliament in Strasbourg.
Dr Tobias Silberzahn is a trained biochemist and immunologist and worked in the life sciences and healthcare space at the consultancy McKinsey & Company for 15 years. There, Tobias worked as a Partner and led McKinsey’s Health Tech Service Line for several years. The focus areas of his work were healthcare innovation, health tech business-building and digital transformation of healthcare.
As part of his work, Tobias supported public health/public sector organisations, foundations/NGOs, health tech startups, investors and corporates in the pharmaceutical, medtech and health insurance space. From a geographic perspective, Tobias has mainly worked in Europe, Africa and Asia.
Tobias grew the Health Tech Network from a small, country-focused community to a global network of >1900 health tech CEOs/Founders, 400 investors and 400 corporate and public sector organisations. Tobias also co-published the "eHealth Monitor Germany", an annual book about the digitisation of the German health system in the Medical Scientific Publishing House Berlin.
In addition to being a core member of the International Lipoprotein(a) Task Force, Tobias is also a Patient Ambassador of FH Europe Foundation.
Tobias holds a PhD in immunology from King's College London and a diploma in biochemistry from Eberhard-Karls-Universität Tübingen (Germany).
teste bio something
Albert Wiegman, Amsterdam, became a paediatrician and member of staff at the Amsterdam University Medical Center in 1991. In 1993, he completed his sub-specialisation in paediatric cardiology, and the Paediatric-Lipid Department came under his care. He started detection and treatment of children with homozygous and heterozygous familial hypercholesterolaemia and other dyslipidaemias in the Netherlands. In 2020, he was appointed Associate Professor and Principal Investigator.
In 30 years, over 4000 children with inherited dyslipidaemias visited his ward. He co-authored around 150 peer-reviewed papers in this field. Since 2024, he was appointed trustee of the Familial Hyperlipidemias Europe Foundation (FH Europe Foundation).
To further the conversation initiated on Lp(a) Awareness Day and at the Lp(a) Global Summit, we held a special webinar today, titled: The Cost-Effectiveness of Lp(a) testing and the Brussels International Declaration on Lp(a) Testing and Management - What does this mean at a country level and how can our community be involved
The session explored key takeaways from the Lp(a) Global Summit, including new research commissioned by the FH Europe Foundation on the cost-effectiveness of Lp(a) testing and the importance of the Brussels International Declaration on Lp(a) Testing and Management.
Prof. Florian Kronenberg (Austria), Prof. Zanfina Ademi (Australia), and Inese Mauriņa (Latvia) shared their impressions from the Summit and perspectives on how the findings could support policy change and action at the national level. The session was moderated by Nicola Bedlington, FH Europe Foundation Sr Policy Advisor
Thank you to the Partners, who contributed to the great success of this Summit.
These organisations play a crucial role in advancing cardiovascular health policies, research, and awareness at the global level.
We are grateful for the support of our industry partners and sponsors who made this event possible. Their contributions enabled critical discussions on cardiovascular health and Lp(a) research to drive meaningful change in healthcare policies and patient outcomes.
For the latest updates on the Lp(a) Global Summit, Lp(a) testing, advocacy and awareness campaigns:
For any questions around the event please contact us via the email below.
